European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice-Reference-Cited by-同舟云学术

European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice

Published:2020-10-15 Issue:6 Volume:34 Page:797-808
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Barbier Liese^ORCID,Simoens Steven^ORCID,Vulto Arnold G.^ORCID,Huys Isabelle^ORCID

Funder

University Medical Center Rotterdam

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s40259-020-00440-z.pdf

Reference34 articles.

1. IQVIA. Advancing biosimilar sustainability in Europe—a multi-stakeholder assessment. 2018. https://www.iqvia.com/insights/the-iqvia-institute/reports/advancing-biosimilar-sustainability-in-europe.

2. IQVIA. The impact of biosimilar competition in Europe. 2018. https://ec.europa.eu/docsroom/documents/31642/attachments/1/translations/en/renditions/native.

3. European Medicines Agency. Biosimilar medicines. https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine/field_ema_med_status/authorised-36/ema_medicine_types/field_ema_med_biosimilar/search_api_aggregation_ema_medicine_types/field_ema_med_biosim. Accessed 12 Jun 2020.

4. IQVIA. The impact of biosimilar competition in Europe. 2019. https://ec.europa.eu/docsroom/documents/38461/attachments/1/translations/en/renditions/native.

5. Simon Kucher & Partners. Payers’ price & market access policies supporting a sustainable biosimilar medicines market. 2016. https://www.medicinesforeurope.com/wp-content/uploads/2016/09/Simon-Kucher-2016-Policy-requirements-for-a-sustainable-biosimilar-market-FINAL-report_for-publication2.pdf.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biosimilars Versus Originators in Children With Juvenile Idiopathic Arthritis: A Real-World Experience;Journal of Pediatric Health Care;2024-08

2. Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review;BioDrugs;2024-06-15

3. Charting the Etanercept Journey: Tracing Cost Dynamics in Poland’s Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly;BioDrugs;2024-06-11

4. Can Endangered Biosimilar Markets be Rescued? The Need to Bridge Competing Interests for Long-Term Gain;BioDrugs;2024-02-26

5. Knowledge and attitudes of German and Swiss community pharmacists towards biologicals and biosimilars – a prospective survey before and after the COVID-19 pandemic;BMC Health Services Research;2023-12-18